Phase 1 Motor Neurone Disease Trial, Recruiting NCT07571174 Sponsor: Eli Lilly and Company Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Phase 1 Motor Neurone Disease Trial, Recruiting

NCT07571174
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have already completed both the main treatment phase and any off-treatment phase of the parent study (called Study OWAA), including any required screening steps from a linked screening protocol.

Who may not be able to join:

  • You have a history of significant back pain, back problems, or back injury (such as spinal surgery, a curved spine, or degenerative back disease) that could make a spinal fluid sample (lumbar puncture) difficult or risky.
  • You are allergic to local anaesthetics such as lidocaine or similar medicines.
  • You have a skin infection at the area of the back where the spinal fluid sample would be taken.
  • Your platelet count (the blood cells that help clotting) is too low, you have a significant blood clotting problem, or you are currently experiencing significant active bleeding.
  • You are currently taking blood-thinning medicines or medicines that affect blood clotting or platelet function — note that a low dose of aspirin (as defined by local medical guidelines) is allowed.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
14 May 2026
Est. completion
1 June 2029

Where this trial is recruiting

🇧🇪 Belgium 🇨🇦 Canada 🇩🇪 Germany 🇳🇱 Netherlands 🇪🇸 Spain

Primary endpoints

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov